Cargando…
A randomized trial of alendronate as prophylaxis against loss in bone mineral density following lymphoma treatment
Lymphoma patients often receive high glucocorticoid doses as part of standard therapy. Observational studies have shown a substantial risk of glucocorticoid-induced osteoporosis (GIO) with associated fractures. The aim of the SIESTA trial was to determine if oral alendronate (ALN) is a safe and effe...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Society of Hematology
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043936/ https://www.ncbi.nlm.nih.gov/pubmed/35045567 http://dx.doi.org/10.1182/bloodadvances.2021006330 |